Vol 71, No 1 (2020)
Clinical vignette
Published online: 2019-10-23
Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma
Abstract
Not required for Clinical Vignette.
Keywords: hypophosphatemiazoledronic acidosteolysismultiple myeloma
References
- Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Recent Results Cancer Res. 2011; 183: 133–147.
- Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne). 2018; 9: 788.
- Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
- Chiam P, Manju C, Chiam P, et al. Profound and protracted hypophosphatemia after a single dose of zoledronic acid infusion for osteoporosis associated with normocalcemic primary hyperparathyroidism. Med Case Rep. 2017; 3: 1–4.
- Torimoto K, Okada Y, Arao T, et al. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J. 2012; 59(12): 1051–1056.
- Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem. 1998; 35 ( Pt 2): 201–206.
